Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors

The capacity of three clinically available nonnucleoside reverse transcriptase inhibitors (NNRTIs) to inhibit the activity of human cytochromes P450 (CYPs) was studied in vitro using human liver microsomes. Delavirdine, nevirapine, and efavirenz produced negligible inhibition of phenacetin O‐deethylation (CYP1A2) or dextromethorphan O‐demethylation (CYP2D6). Nevirapine did not inhibit hydroxylation of tolbutamide (CYP2C9) or S‐mephenytoin (CYP2C19), but these CYP isoforms were importantly inhibited by delavirdine and efavirenz. This indicates the likelihood of significantly impaired clearance of CYP2C substrate drugs (such as phenytoin, tolbutamide, and warfarin) upon initial exposure to these two NNRTIs. Delavirdine and efavirenz (but not nevirapine) also were strong inhibitors of CYP3A, consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A. The in vitro microsomal model provides relevant predictive data on probable drug interactions with NNRTIs when the mechanism is inhibition of CYP‐mediated drug biotransformation. However, the model does not incorporate interactions attributable to enzyme induction.

[1]  D. E. Smith,et al.  Steady‐state pharmacokinetics of delavirdine in HIV‐positive patients: Effect on erythromycin breath test , 1997, Clinical pharmacology and therapeutics.

[2]  M. Otero,et al.  Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. , 1999, AIDS.

[3]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[4]  D. Greenblatt,et al.  Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. , 1994, British journal of clinical pharmacology.

[5]  David Back,et al.  Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection , 1999, Clinical pharmacokinetics.

[6]  D. Greenblatt,et al.  Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. , 1993, Pharmacology.

[7]  R. Yuan,et al.  Pharmacokinetic and Pharmacodynamic Consequences of Metabolism‐Based Drug Interactions with Alprazolam, Midazolam, and Triazolam , 1999, Journal of clinical pharmacology.

[8]  D. Greenblatt,et al.  Alprazolam‐ritonavir interaction: Implications for product labeling , 2000, Clinical pharmacology and therapeutics.

[9]  D. Greenblatt,et al.  Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole , 2000, European Journal of Clinical Pharmacology.

[10]  K. Koeplinger,et al.  Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. , 1998, The Journal of pharmacology and experimental therapeutics.

[11]  D. Greenblatt,et al.  Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. , 1996, Pharmacology.

[12]  E. De Clercq,et al.  Managing resistance to anti-HIV drugs: an important consideration for effective disease management. , 1999, Drugs.

[13]  K. Thummel,et al.  In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.

[14]  D. Greenblatt,et al.  In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors , 2000, Biological Psychiatry.

[15]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[16]  D. Greenblatt,et al.  Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences , 1998, Clinical pharmacology and therapeutics.

[17]  D. Greenblatt,et al.  Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. , 2000, The Journal of pharmacology and experimental therapeutics.

[18]  D. Greenblatt,et al.  Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir , 1998, Journal of clinical pharmacology.

[19]  Lauren B. Meade,et al.  Methadone Withdrawal when Starting an Antiretroviral Regimen Including Nevirapine , 1999, Pharmacotherapy.

[20]  D. Back,et al.  Protease Inhibitors in Patients with HIV Disease , 1997, Clinical pharmacokinetics.

[21]  D. Greenblatt,et al.  In vitro approaches to predicting drug interactions in vivo. , 1998, Biochemical pharmacology.

[22]  D. Greenblatt,et al.  Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine , 1996, Psychopharmacology.

[23]  R. Rando.  Mechanism-based enzyme inactivators. , 1984, Pharmacological reviews.

[24]  J S Harmatz,et al.  Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.

[25]  J. Gerber,et al.  Neither dapsone hydroxylation nor cortisol 6β-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors , 1998, European Journal of Clinical Pharmacology.

[26]  J S Harmatz,et al.  Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. , 1996, The Journal of pharmacology and experimental therapeutics.

[27]  D. Back,et al.  Antiretroviral therapy for patients with HIV disease. , 1998, British journal of clinical pharmacology.

[28]  D. Greenblatt,et al.  Effects of the Antifungal Agents on Oxidative Drug Metabolism , 2000, Clinical pharmacokinetics.

[29]  D. Greenblatt,et al.  Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. , 1998, Journal of pharmaceutical sciences.

[30]  D. Greenblatt,et al.  Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. , 1998, Journal of pharmaceutical sciences.

[31]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[32]  D. Greenblatt,et al.  Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.

[33]  D. Ostrow,et al.  Psychosocial and Public Health Impacts of New HIV Therapies , 2002, AIDS Prevention and Mental Health.

[34]  A. Hsu,et al.  Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. , 1998, Clinical pharmacokinetics.

[35]  D. Greenblatt,et al.  Pharmacokinetics of Protease Inhibitors and Drug Interactions with Psychoactive Drugs , 2002 .

[36]  D. Greenblatt,et al.  Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In‐vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A , 1998, The Journal of pharmacy and pharmacology.

[37]  A. D. Rodrigues,et al.  Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. , 1999, Biochemical pharmacology.

[38]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[39]  Andrew Carr,et al.  HIV protease inhibitors , 1996, AIDS.

[40]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[41]  F. Altice,et al.  Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. , 1999, AIDS.

[42]  R H Levy,et al.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[43]  D. Greenblatt,et al.  Metabolism of Dextromethorphan in vitro: Involvement of Cytochromes P450 2D6 AND 3A3/4, with a Possible Role of 2E1 , 1997, Biopharmaceutics & drug disposition.

[44]  J. Ferry,et al.  Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[45]  D. Greenblatt,et al.  Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects , 1999, Biological Psychiatry.

[46]  D. Greenblatt,et al.  Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. , 1999, Journal of clinical psychopharmacology.